S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

CorMedix Stock Forecast, Price & News

+0.07 (+1.43%)
(As of 11/30/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
143,625 shs
Average Volume
574,434 shs
Market Capitalization
$189.67 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CorMedix and its competitors with MarketBeat's FREE daily newsletter.

CorMedix logo

About CorMedix

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.


Cormedix's Return On Capital Employed Insights
November 9, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$240 thousand
Book Value
$1.38 per share


Net Income
$-22.03 million
Net Margins
Pretax Margin




Free Float
Market Cap
$189.67 million

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.94 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

Is CorMedix a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CorMedix stock.
View analyst ratings for CorMedix
or view top-rated stocks.

How has CorMedix's stock price been impacted by Coronavirus (COVID-19)?

CorMedix's stock was trading at $5.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRMD stock has decreased by 0.8% and is now trading at $4.98.
View which stocks have been most impacted by COVID-19

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) released its earnings results on Monday, November, 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.04. CorMedix had a negative trailing twelve-month return on equity of 39.16% and a negative net margin of 13,952.10%.
View CorMedix's earnings history

When did CorMedix's stock split? How did CorMedix's stock split work?

CorMedix's stock reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRMD?

3 analysts have issued 12 month price targets for CorMedix's shares. Their forecasts range from $13.50 to $29.00. On average, they anticipate CorMedix's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 311.6% from the stock's current price.
View analysts' price targets for CorMedix
or view top-rated stocks among Wall Street analysts.

Who are CorMedix's key executives?

CorMedix's management team includes the following people:
  • Mathew David, Executive VP, Chief Executive & Financial Officer
  • Antony E. Pfaffle, Secretary & Chief Scientific Officer
  • Elizabeth Masson-Hurlburt, Executive Vice President & Head-Clinical Operation
  • Phoebe Mounts, EVP, General Counsel, Head-Regulatory & Compliance
  • Thomas Nusbickel, Chief Commercial Officer

What other stocks do shareholders of CorMedix own?

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.58%), Geode Capital Management LLC (1.76%), Morgan Stanley (0.97%), Two Sigma Advisers LP (0.42%), Two Sigma Investments LP (0.34%) and Bank of New York Mellon Corp (0.32%). Company insiders that own CorMedix stock include Alan W Dunton, Elizabeth Masson-Hurlburt, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts and Steven W Lefkowitz.
View institutional ownership trends for CorMedix

Which major investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, State Board of Administration of Florida Retirement System, Two Sigma Advisers LP, California State Teachers Retirement System, Jane Street Group LLC, Barclays PLC, Citadel Advisors LLC, and Private Advisor Group LLC.
View insider buying and selling activity for CorMedix
or view top insider-selling stocks.

Which major investors are buying CorMedix stock?

CRMD stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Geode Capital Management LLC, SG Americas Securities LLC, Advisory Services Network LLC, BlackRock Inc., Invesco Ltd., and Beacon Pointe Advisors LLC. Company insiders that have bought CorMedix stock in the last two years include Alan W Dunton, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix
or or view top insider-buying stocks.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $4.98.

How much money does CorMedix make?

CorMedix has a market capitalization of $189.67 million and generates $240 thousand in revenue each year. The biotechnology company earns $-22.03 million in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does CorMedix have?

CorMedix employs 35 workers across the globe.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

Where are CorMedix's headquarters?

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at (908) 517-9500 or via fax at 908-429-4307.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.